Dimericine

Treatment for Skin Cancer

AGI Dermatics 'Breakthrough' Anti-Aging Cream is Singled out by Three Major Media Outlets -- CBS's the Early Show, Prevention Magazine, and Dermatology Times


Dimericine's Potential for Skin Cancer Prevention Described by Leading Dermatologist

FREEPORT, N.Y., March 9, 2005--Applied Genetics Inc. (AGI) Dermatics, a world leader in DNA repair technology, announced today that its DNA repair lotion, Dimericine, was hailed as a "breakthrough" during the month of February by three well respected news sources, including CBS's The Early Show (2/28), Prevention Magazine (March issue), and Dermatology Times (Feb. issue), the leading newsmagazine for dermatologists.

Daniel B. Yarosh, President of AGI Dermatics, says, "The outpouring of recent news coverage supports the exciting and truly 'breakthrough' possibilities of Dimericine, a DNA repair lotion that is awaiting FDA approval."

AGI was touted for the important innovation of "Dimericine, a biotech cream currently in clinical trials, poised to become the first skin repair drug," by CBS's The Early Show in its Medical Breakthroughs report that highlighted this month's Prevention Magazine's feature article, Best Beauty Breakthroughs - 8 Top Innovations Straight from the labs that can make a real difference in the way you look.

The Prevention Magazine article described Dimericine's impact: "In tests on humans who were extremely sensitive to sunlight, Dimericine reduced the incidence of skin cancer by a third and the number of precancers by two-thirds. If used daily, experts say, this lotion will very likely reduce the occurrence of basal and squamous cell skin cancer and possibly malignant melanoma."

Dr. Yarosh explains, "We are pleased that the Prevention Magazine article recognized the unique biomolecular challenge in creating Dimericine. The article states, "A bacterial enzyme--T4 endonuclease V - has been known for decades to repair damaged DNA strands in a test tube. The challenge was getting that enzyme into the nucleus of the skin cell, where its genetic material resides. Molecular biologist Daniel B. Yarosh, PhD, and his colleagues at Applied Genetics Inc in Freeport, NY, accomplished this feat by enveloping T4 endonuclease V in a fat bubble called T4N5 liposome, which can penetrate a skin cell."

Says Dr.Yarosh, "We also take special note of the critical review we received from Dermatology Times. They wrote, 'When it comes to potential topical treatments for actinic keratoses (AKs) and non-melanoma skin cancers, T4N5 liposome lotion (Dimericine, AGI,) leads the pack.'"

Nancy Han, MD, PhD, a dermatologist at the Palo Alto Medical Foundation in California who has extensive experience in this area, explains in the article, "If we can repair DNA efficiently after UV exposure, then we would have fewer and, hopefully, no mutations in our DNA -and therefore lower the risk of skin cancer."

Dr. Han continued, "With these results, not only were researchers able to show delivery of this protein through the stratum corneum, but they also demonstrated that these enzymes are functionally active. It's very exciting. Dimericine would be used a chemopreventive agent, with sunblock to be used before UV exposure and Dimericine after."

About Applied Genetics Inc. Dermatics
AGI Dermatics is the world leader in DNA repair technology. The Company develops new molecular biology technology for photoaging and skin cancer prevention. These products are based on the Company's proprietary drug delivery technology centered on liposomes for skin. AGI Dermatics is commercializing products that repair DNA and restore health that has been damaged by age or the environment, tracking the demands of our changing demographics. Ingredients made by AGI Dermatics are found in hundreds of prestige products sold by the major cosmetic companies around the world.

Posted: March 2005

Dimericine (T4N5 Liposome Lotion) FDA Approval History

View comments

Hide
(web4)